Keith Dionne serves as an entrepreneur-in-residence at Third Rock focusing on drug discovery and development opportunities across our portfolio.
- Former president and chief executive officer of Constellation Pharmaceuticals
Keith is an industry veteran with 20 years of experience leading U.S. and international biotechnology companies. Most recently, he was president and CEO of Constellation Pharmaceuticals – an oncology focused epigenetics company. Prior to joining Constellation, he served as an entrepreneur-in-residence at Third Rock Ventures. Before that, he served as CEO at Surface Logix, Inc. which was acquired by Nano Terra, Inc. Keith was the president and CEO of Alantos Pharmaceuticals, leading the company’s acquisition by Amgen for more than $300 million in 2007. Prior to joining Alantos, Keith was with Millennium Pharmaceuticals (now Takeda) where he held positions of increasing responsibility, concluding his seven-year tenure as both vice president of R&D strategy and vice president and general manager, technology business. Keith was head of implantable drug delivery research at ALZA Pharmaceuticals where he led the development of Viadur™ a 12-month treatment for prostate cancer. He was one of four original scientists at CytoTherapeutics, a cell transplantation company. Keith served as an adjunct professor in the Biomedical Department at Brown University. He received both his Ph.D. in chemical engineering and his MS in the program for technology policy from MIT.
Keith is an assistant wrestling coach at Belmont High school where his son Max wrestles at 138 lbs.